Synlett 2016; 27(11): 1607-1612
DOI: 10.1055/s-0035-1561440
synpacts
© Georg Thieme Verlag Stuttgart · New York

Combined Chemo-Anti-Inflammatory Prodrugs and Nanoparticles

Rakesh K. Pathak, Shanta Dhar*
  • NanoTherapeutics Research Laboratory, Department of Chemistry, University of Georgia, Athens, GA 30602, USA   eMail: shanta@uga.edu
Weitere Informationen

Publikationsverlauf

Received: 05. Januar 2016

Accepted after revision: 21. März 2016

Publikationsdatum:
22.April 2016 (eFirst)

Abstract

Combining multiple drugs in one platform has the ability to override the limitations of singly administered therapeutic and may provide potential alternative treatment options for aggressive prostate cancer resistant to conventional chemotherapy. For in vivo applications, combination therapeutics should be engineered to include nanoparticles for efficacious delivery. Here, we discuss the aspects of combining chemotherapy with anti-inflammatory drugs for metastatic castration resistant prostate cancer. We highlight the concept of combining cisplatin and Aspirin in a single platinum(IV) prodrug for efficacious in vitro biological actions. These two drugs were further incorporated in an engineered biodegradable polymer, which can self-assemble in the presence of a block copolymer to controlled-release nanoparticles to deliver multiple therapeutics in a predefined ratio.

1 Introduction

2 Chemo-Anti-inflammatory Approaches for Chemo-Resistant Prostate Cancer: Challenges and Opportunities

3 Chemo-Anti-inflammatory Platinum(IV) Prodrugs

4 Polymeric Nanoparticle for Co-delivery of Cisplatin and Aspirin

5 Future Perspectives